Treats stable, symptomatic (NYHA Class II or III) heart failure of ischemic…. ANDA 204106, held by Novast Labs. Metoprolol Succinate.
As of Nov 16, 2026, ANDA 204106 (Metoprolol Succinate), held by Novast Labs, was first approved by FDA on Feb 6, 2018, with 2 approved supplements and 0 published complete response letters.
Metoprolol succinate, is a beta 1 -selective adrenoceptor blocking agent. Metoprolol succinate extended-release tablets, USP are indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 6, 2018 | Original application | Approved | None posted |
| Metoprolol SuccinateEQ 25MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 50MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 100MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 200MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Jun 28, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jun 28, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 6, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters